Investor Relations

Prometheus Biosciences is a biotech company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic product candidates. While our initial focus was on IBD, we're now extending beyond gastrointestinal (GI) diseases to target other autoimmune diseases.

Prometheus360TM, our powerful precision medicine platform, combines proprietary technology with the world's most comprehensive collection of IBD patient data, to translate deep, complex data into precision therapeutic and diagnostic product candidates and continually identify new drug targets and unique disease biomarkers. We're headquartered in San Diego, CA.


Investor Relations


Find SEC filings, quarterly results, and annual reports.


See charters and documents from the Prometheus Biosciences Board of Directors.

IR Contact

For investor questions only. Please contact:

Noel Kurdi

Data Provided by Refinitiv. Minimum 15 minutes delayed.